Etomidate is a short-acting sedative given intravenously to put patients to sleep before surgery or medical procedures. It works within about one minute and lasts only three to five minutes at a standard dose, making it one of the fastest-acting anesthetics available. Its main advantage is that it causes very little drop in blood pressure, which is why it’s often chosen for patients who are critically ill, in shock, or have heart problems.
How Etomidate Works in the Brain
Etomidate produces unconsciousness by amplifying the activity of GABA receptors, the brain’s primary “off switch” for nerve signaling. GABA is a chemical messenger that calms neural activity. Etomidate binds to a specific spot on these receptors and makes them more sensitive to GABA, so the brain’s inhibitory signals become much stronger than normal. The result is a rapid loss of consciousness.
At low concentrations, etomidate boosts the effect of GABA that’s already present. At higher concentrations, it can actually open these receptors on its own, without GABA. Both effects push the brain into a deeply sedated state within seconds of injection.
When It’s Used
The primary use of etomidate is “induction,” the step where a patient goes from awake to unconscious at the start of general anesthesia. It’s also commonly used to sedate patients for emergency intubation, the process of placing a breathing tube. Because it barely affects blood pressure or heart rate, it’s a go-to choice in trauma bays, emergency departments, and ICUs when patients are already hemodynamically fragile. Other sedatives like propofol can cause significant blood pressure drops, which makes etomidate the safer pick for someone who’s lost blood, is in septic shock, or has a weak heart.
Nearly half of critically ill patients who receive mechanical ventilation in U.S. hospitals get etomidate on the day their breathing tube is placed, according to a large analysis of hospital data from 2008 to 2021.
What to Expect: Onset, Duration, and Recovery
After injection, you’ll lose consciousness within about 60 seconds. At the standard dose of 0.3 mg/kg of body weight, the effect lasts roughly three to five minutes. The drug is cleared from the bloodstream in two phases: levels drop quickly in the first 30 minutes, then taper off more slowly with a half-life of about 75 minutes. For patients with liver disease (such as cirrhosis), the drug stays in the body roughly twice as long.
Because of its short duration, etomidate is almost always followed by other medications to maintain sedation or anesthesia. It’s a “door opener,” not a drug designed to keep you under for an entire procedure.
Common Side Effects
The most noticeable side effect is myoclonus, involuntary jerking or twitching of the muscles that happens as the drug takes effect. This occurs in 50 to 80 percent of patients and can look alarming, but it isn’t a seizure and doesn’t cause harm. It happens because the drug suppresses some brain areas faster than others, temporarily releasing motor pathways from normal inhibition. Pretreatment with other medications can reduce myoclonus, and medical teams often plan for it.
Other common side effects include pain at the injection site and postoperative nausea and vomiting. These tend to be mild and short-lived given the drug’s brief duration of action.
The Cortisol Suppression Concern
Etomidate’s biggest drawback is that it temporarily shuts down your adrenal glands’ ability to produce cortisol, the stress hormone your body needs to maintain blood pressure and fight infection. It does this by blocking an enzyme called 11-beta-hydroxylase, which is essential for the final step of cortisol production. Even a single dose suppresses cortisol levels for up to 24 to 48 hours.
During and after etomidate administration, blood levels of the hormone that signals the adrenals to make cortisol (ACTH) actually rise, while cortisol itself falls. The adrenal glands are trying to respond but can’t complete the manufacturing process. Precursor hormones build up in the blood while finished cortisol drops.
For a healthy person undergoing elective surgery, this temporary suppression rarely matters. But for critically ill patients who depend on their stress response, it can be dangerous. A large matched study comparing etomidate to ketamine (another sedative with stable blood pressure effects) in over 22,000 critically ill patient pairs found that those who received etomidate had a hospital mortality rate of 21.6%, compared to 18.7% for ketamine. That 2.8 percentage point difference persisted across patient subgroups, and giving corticosteroids afterward did not eliminate the increased risk. This finding, published in the American Journal of Respiratory and Critical Care Medicine, has intensified debate about whether etomidate should still be used in ICU settings.
Who Should Not Receive It
The only absolute contraindication is a known allergy to etomidate. In practice, many clinicians avoid it in patients with sepsis or adrenal insufficiency because of the cortisol suppression issue. The decision often comes down to a tradeoff: the drug’s unmatched blood pressure stability versus the risk of worsening adrenal function in someone whose body is already struggling to mount a stress response.
For patients with liver disease, the drug is used cautiously because it takes roughly twice as long to clear from the body, extending both its effects and its adrenal suppression.